Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer

BACKGROUND: This randomised, double-blind study compared pharmacokinetics, efficacy, safety and immunogenicity of PF-05280014 (potential trastuzumab biosimilar) and trastuzumab reference product (Herceptin) sourced from the European Union (trastuzumab-EU) as neoadjuvant treatment for operable human...

Descripción completa

Detalles Bibliográficos
Autores principales: Lammers, Philip E., Dank, Magdolna, Masetti, Riccardo, Abbas, Richat, Hilton, Fiona, Coppola, Jennifer, Jacobs, Ira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068194/
https://www.ncbi.nlm.nih.gov/pubmed/30002437
http://dx.doi.org/10.1038/s41416-018-0147-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068194/
https://www.ncbi.nlm.nih.gov/pubmed/30002437
http://dx.doi.org/10.1038/s41416-018-0147-1

Ejemplares similares